ENDRA Life Sciences Files S-1/A Amendment

TL;DR

ENDRA Life Sciences filed an S-1/A amendment, likely for securities registration. Stay tuned.

AI Summary

ENDRA Life Sciences Inc. filed an S-1/A amendment on May 31, 2024, related to its registration statement (No. 333-278842). The company, incorporated in Delaware and headquartered in Ann Arbor, MI, is in the electromedical apparatus industry. This filing is an amendment to a previous registration, indicating ongoing efforts to register securities.

Why It Matters

This filing is an update to ENDRA Life Sciences' registration statement, which is a necessary step for companies looking to offer securities to the public.

Risk Assessment

Risk Level: medium — S-1/A filings are typically related to securities offerings, which inherently carry market and regulatory risks.

Key Numbers

• 333-278842 — SEC Registration Number (Identifies the specific registration statement being amended.)

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — Registrant
• 333-278842 (registration_number) — SEC Registration Number
• May 31, 2024 (date) — Filing Date
• Ann Arbor, MI (location) — Principal Executive Offices
• Francois Michelon (person) — Chief Executive Officer

FAQ

Key Financial Figures

• $0.0001 — 2,546 shares of common stock, par value $0.0001 per share ("common stock"), together wi
• $0.001 — exercise of the Series B Warrant using $0.001 as the exercise price for that purpose
• $0.267 — poses of this preliminary prospectus is $0.267 (equal to the last sale price of our co
• $1 million — sive—a CT system can cost approximately $1 million and an MRI system can cost up to approx
• $3 million — MRI system can cost up to approximately $3 million. In addition, and in contrast to ultras
• $5,000 — ems can cost as little as approximately $5,000 and the price of new cart-based ultraso
• $75,000 — nd systems can range from approximately $75,000 to $200,000. These numbers include both
• $200,000 — can range from approximately $75,000 to $200,000. These numbers include both portable an
• $65,000 — ystem at a price point of approximately $65,000, which we believe could enable clinical

Filing Documents

• endra_s1a.htm (S-1/A) — 402KB
• endra_ex42.htm (EX-4.2) — 135KB
• endra_ex43.htm (EX-4.3) — 117KB
• endra_ex51.htm (EX-5.1) — 14KB
• endra_ex231.htm (EX-23.1) — 2KB
• endra_ex107.htm (EX-FILING FEES) — 48KB
• endra_s1img6.jpg (GRAPHIC) — 8KB
• endra_s1img5.jpg (GRAPHIC) — 28KB
• endra_s1img4.jpg (GRAPHIC) — 9KB
• endra_ex51img1.jpg (GRAPHIC) — 2KB
• 0001654954-24-007150.txt ( ) — 785KB

USE OF PROCEEDS

USE OF PROCEEDS 11 CAPITALIZATION 12

DILUTION

DILUTION 13 DESCRIPTION OF OUR SECURITIES 14 PLAN OF DISTRIBUTION 21 LEGAL MATTERS 23 EXPERTS 23 WHERE YOU CAN FIND MORE INFORMATION 23 INCORPORATION BY REFERENCE 24 You should rely only on the information contained in this prospectus. Neither we nor the Placement Agent has authorized anyone to provide you with different information and, if provided, such information or representations must not be relied upon as having been authorized by us or the Placement Agent. This prospectus shall not constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. You should read this prospectus together with the additional information described below under the heading " Where You Can Find More Information ." We may also provide a prospectus supplement or post-effective amendment to the Registration Statement to add information to, or update or change information contained in, this prospectus. This prospectus does not contain all of the information included in the Registration Statement. For a more complete understanding of the offering of the securities, you should refer to the Registration Statement, including its exhibits. Unless the context indicates otherwise, in this prospectus, the terms "ENDRA," "we," "us," "our," and the "Company" refer to ENDRA Life Sciences Inc., a Delaware corporation, and its subsidiaries. iii Table of Contents CAUTIONARY NOTEREGARDING FORWARD-LOOKING STATEMENTS This prospectus contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use

View Full Filing

View this S-1/A filing on SEC EDGAR